Matthew Pauls, Director at Pelthos Therapeutics Inc. (PTHS), sold 786 shares at $26.00 ($21K) on 2026-07-02, disclosed to the SEC on 2026-07-07.
Scheduled sale ($21k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.00 | 692 | $18K | 87.5% |
| 2 | $27.36 | 94 | $3K | 12.5% |
| Total | $26.16 avg | 786 | $21K | 100% |
| Filing → |
| SVRA | SELL | 2024-12-16 | $362K | — | Filing → |
| SVRA | SELL | 2023-12-29 | $396K | — | Filing → |
| SVRA | BUY | 2021-12-08 | $7K | — | Filing → |